Intercept Pharmaceuticals, Inc. (ICPT)
| Market Cap | 480.53M |
| Revenue (ttm) | 341.03M |
| Net Income (ttm) | -170.13M |
| Shares Out | 33.18M |
| EPS (ttm) | -5.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 354,097 |
| Open | 16.74 |
| Previous Close | 16.90 |
| Day's Range | 16.30 - 17.17 |
| 52-Week Range | 11.60 - 40.41 |
| Beta | 1.43 |
| Analysts | Buy |
| Price Target | 29.61 (+72.9%) |
| Est. Earnings Date | Oct 28, 2021 |
About ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in vario...
Financial Performance
In 2020, ICPT's revenue was $312.69 million, an increase of 24.08% compared to the previous year's $252.00 million. Losses were -$274.88 million, -20.25% less than in 2019.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for ICPT stock is "Buy." The 12-month stock price forecast is 29.61, which is an increase of 72.85% from the latest price.
News
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) and Encourages L...
Philadelphia, Pennsylvania--(Newsfile Corp. - October 23, 2021) - Kaskela Law LLC announces that it is investigating Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) on beha...
Wall Street Analysts Think Intercept (ICPT) Could Surge 95%: Read This Before Placing a Bet
The mean of analysts' price targets for Intercept (ICPT) points to a 94.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...
7 Short-Interest Stocks That Could Be Bull Traps
While betting on short-interest stocks has become a popular speculation tactic, you want to be careful about this fad. The post 7 Short-Interest Stocks That Could Be Bull Traps appeared first on Investo...
Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pr...
3 Most-Shorted Stocks to Buy
Off and on the price chart, these three most-shorted stocks – found after we've searched high and low – have the goods to rally. The post 3 Most-Shorted Stocks to Buy appeared first on InvestorPlace.
5 Stocks With 195% to 467% Upside, According to Wall Street
If these high-water price targets come to fruition, investors will be all smiles.
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest This Week
We're seeing loads of interest from investors targeting short-squeeze stocks this week as meme rallies push several shares higher. The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest T...
Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pr...
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeuti...
5 Growth Stocks With 110% to 393% Upside, According to Wall Street
Analysts are calling for significant gains in these fast-paced stocks.
Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat
Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates
Intercept (ICPT) delivered earnings and revenue surprises of 73.39% and 16.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals: Q2 Earnings Insights
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) moved higher by 3.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 82.81% year over year to ($0...
Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter
Earnings Outlook For Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) unveils its next round of earnings this Thursday, July 29. Get prepared with Benzinga's ultimate preview for Intercept Pharmaceuticals's Q2 earnings.
Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021
The biotech can't seem to catch a break.
Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021
NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
Intercept to Present at the Raymond James 2021 Human Health Innovation Conference
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
Are These the Next Meme Stocks?
Reddit's retail investors may soon be swooning over this under-the-radar trio of heavily short-sold companies.
Intercept Appoints M. Michelle Berrey, M.D.
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
Intercept (ICPT) Moves 8% Higher: Will This Strength Last?
Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength do...
Intercept (ICPT) Ocaliva's Prescribing Information Updated
Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.
Intercept Announces Updated Ocaliva® (obeticholic acid) U.S. Prescribing Information
New contraindication applies to a subset of patients with primary biliary cholangitis (PBC) with decompensated cirrhosis, a prior decompensation event, or with compensated cirrhosis who have evidence of...